文献速递妇科

子宫浆液性癌:ESGO/GCIG/JGOG罕见肿瘤工作组叙述性综述

Uterine serous carcinoma.
PubMed 文献 · Gynecol Oncol · 2021-04-30

子宫浆液性癌约占子宫内膜癌的10%,却导致40%的子宫内膜癌相关死亡。该综述由ESGO、GCIG和JGOG的罕见肿瘤工作组撰写,总结其标准与新兴治疗选择,指出TCGA分类中多属拷贝数高组,TP53突变率90%,帕博利珠单抗联合仑伐替尼二线治疗晚期/复发患者应答率50%,临床试验为优先。

要点

  • 浆液性癌约占子宫内膜癌10%,却占相关死亡40%
  • 治疗以手术、化疗和/或放疗的多模式为主,生存仍差
  • 帕博利珠单抗联合仑伐替尼二线治疗应答率50%

核心结论

  • 浆液性子宫内膜癌虽相对少见但预后差,标准多模式治疗后生存仍不理想,临床试验应优先考虑。

研究设计与样本

  • 由ESGO、GCIG和JGOG成员组成的罕见肿瘤工作组开展的叙述性综述。

主要发现

  • 浆液性癌约占所有诊断子宫内膜癌的10%,但占子宫内膜癌相关死亡的40%。
  • 与子宫内膜样亚型相比,浆液性癌分期对应时复发风险更高、预后更差。
  • 浆液性癌以显著核异型性和免疫组化p53异常染色为特征。
  • TCGA分类中浆液性癌多属「拷贝数高」组,特征为细胞周期失调相关基因改变和TP53突变(90%)。
  • 帕博利珠单抗联合仑伐替尼在晚期/复发浆液性子宫内膜癌二线治疗中应答率为50%。

关键数值与推荐

  • 浆液性癌约占子宫内膜癌的10%。
  • 浆液性癌占子宫内膜癌相关死亡的40%。
  • 「拷贝数高」组中TP53突变率为90%。
  • 帕博利珠单抗联合仑伐替尼二线治疗晚期/复发浆液性子宫内膜癌应答率为50%。

临床怎么用

  • 新诊断浆液性子宫内膜癌以手术、化疗和/或放疗的多模式治疗为主。
  • 晚期/复发患者二线可考虑帕博利珠单抗联合仑伐替尼。
  • 因肿瘤常为p53+和pMMR,PD-1抑制剂单药治疗应答可能性低,宜选联合策略。
  • 鉴于预后不佳,应优先鼓励患者参加临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. Patients with serous endometrial cancer are often diagnosed at earlier disease stage, but remain at higher risk of recurrence and poorer prognosis when compared stage-for-stage with endometrioid subtype endometrial cancer. Serous endometrial cancers are characterized by marked nuclear atypia and abnormal p53 staining in immunohistochemistry. The mainstay of treatment for newly diagnosed serous endometrial cancer includes a multi-modal therapy with surgery, chemotherapy and/or radiotherapy. Unfortunately, despite these efforts, survival outcomes still remain poor. Recently, The Cancer Genome Atlas (TCGA) Research Network classified all endometrial cancer types into four categories, of which, serous endometrial cancer mostly is found within the "copy number high" group. This group is characterized by the increased cell cycle deregulation (e.g., CCNE1, MYC, PPP2R1A, PIKCA, ERBB2 and CDKN2A) and TP53 mutations (90%). To date, the combination of pembrolizumab and lenvatinib is an effective treatment modality in second-line therapy, with a response rate of 50% in advanced/recurrent serous endometrial cancer. Owing to the unfavorable outcomes of serous endometrial cancer, clinical trials are a priority. At present, ongoing studies are testing novel combinations of various targeted and immunotherapeutic agents in newly diagnosed and advanced/recurrent endometrial cancer - an important strategy for serous endometrial cancer, whereby tumors are usually p53+ and pMMR, making response to PD-1 inhibitor monotherapy unlikely. Here, the rare tumor working group (including members from the European Society of Gynecologic Oncology (ESGO), Gynecologic Cancer Intergroup (GCIG), and Japanese Gynecologic Oncology Group (JGOG)), performed a narrative review reporting on the current landscape of serous endometrial cancer and focusing on standard and emerging therapeutic options for patients affected by this difficult disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Bogani G, Ray-Coquard I, Concin N, et al. Uterine serous carcinoma. Gynecol Oncol. 2021. PMID: 33934848. doi:10.1016/j.ygyno.2021.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。